Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants

Blumberg, Dean A.; Mink, Chris Anna M.; Cherry, James D.; Johnson, Carrie; Garber, Rachel; Plotkin, Stanley А.; Watson, Barbara; Ballanco, Gerard A.; Daum, Robert S.; Sullivan, Bradley J.; Townsend, Timothy R.; Brayton, James; Gooch, W. Manford; Nelson, David B.; Congeni, Blaise L.; Prober, Charles G.; Hackell, Jill G.; Dekker, Cornelia L.; Christenson, Peter D.

doi:10.1016/s0022-3476(05)80727-9

Cited by 63 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The acellular and whole-cell vaccines used in this and our previous study contained the same quantity of diphtheria and tetanus toxoids but induced dierent antibody responses. A number of other investigators have demonstrated lower antitoxoid responses following immunisation with DTaP vaccines [3,7,9,19,22,30,33,35,36], but others have found similar or higher responses with acellular products, particularly those with a greater content of diphtheria or tetanus toxoid [13,17,21]. Our results taken with those of others suggest that combining diphtheria and tetanus toxoids with acellular rather than whole-cell vaccines results in a modest reduction in immunogenicity.…”

Section: Discussionsupporting

confidence: 65%

Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule

Bell¹,

Heath

MacLennan

et al. 1999

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 65%

Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule

Bell¹,

Heath

MacLennan

et al. 1999

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…The acellular vaccines were much less likely to cause reactions than the whole-cell vaccine, as shown previously. [24][25][26][27] The same pattern was observed in an Italian trial, reported in this issue of the Journal, which used the same wholecell vaccine, two three-component vaccines, and a different DT-vaccine control. 28 A temperature of 40.5°C or higher and convulsions are contraindications for additional doses of whole-cell vaccine, and the 1994 Red Book 29 advises physicians to consider carefully an individual patient's history before vaccination.…”

Section: Discussionmentioning

confidence: 64%

A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine

et al. 1996

View full text Add to dashboard Cite

show abstract

“…The acellular pertussis vaccine is immunogenic and is effective in preventing pertussis but less reactogenic than the wP vaccine [ 19 ]. However, compared with the best wP vaccines, aP vaccines are not as effective in mass immunization programs [ 5 , 20 ].…”

Section: Efficacy and Effectivenessmentioning

confidence: 99%

Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy

et al. 2022

View full text Add to dashboard Cite

Pertussis is a common respiratory infection caused by the bacterium Bordetella pertussis. Although most cases occur in developing countries, it is considered endemic globally. The World Health Organization estimates there are 20 to 40 million cases of pertussis annually. Pertussis vaccines played a pivotal role in reducing the burden of pertussis disease as well as in infant morbidity and mortality. Although the two forms of pertussis vaccine are effective, each has its advantages and drawbacks. This paper aims to review the current knowledge on pertussis vaccine, emphasizing vaccine effectiveness in different populations in a community. Clinical trials have shown favorable vaccine efficacy with acellular pertussis (aP) vaccine. However, observation and population-level studies showed that introducing at least a single dose of whole-cell pertussis (wP) vaccine within the routine immunization schedule is associated with better disease protection and a longer duration of immunity. On the other hand, wP vaccine is more reactogenic and associated with higher adverse events. Therefore, the selection of vaccine should be weighed against the effectiveness, reactogenicity, and cost-effectiveness. Due to its safety profile, aP vaccine can be offered to wider population groups. Booster adolescent and pregnant immunization programs have been implemented globally to control outbreaks and protect vulnerable infants. Due to the variable effectiveness performance of both vaccines, different countries adopted distinctive immunization programs. Determining the right vaccination approach depends on financial consideration, immunization program infrastructure, adverse event monitoring, and pertussis surveillance in the community.

show abstract

Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants

Cited by 63 publications

References 21 publications

Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule

Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule

A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine

Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy

Contact Info

Product

Resources

About